scholarly journals Characteristics of Humoral Regulation of Differentiation of Bone Marrow Monocyte Subpopulations in Patients with Ischemic Cardiomyopathy

2019 ◽  
Vol 9 (2) ◽  
pp. 91-96
Author(s):  
Olga Urazova ◽  
Svetlana Chumakova ◽  
Maria Vins ◽  
Elena Maynagasheva ◽  
Vladimir Shipulin ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Ischemic Cardiomyopathy ◽  
Monocyte Subpopulations ◽  
Humoral Regulation

scholarly journals Monocyte subpopulations of blood and bone marrow in patients with chronic heart failure

2018 ◽  
Vol 17 (4) ◽  
pp. 16-22
Author(s):  
M. V. Vins ◽  
S. P. Chumakova ◽  
O. I. Urazova ◽  
D. A. Azarova ◽  
V. M. Shipulin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Bone Marrow ◽  
Chronic Heart Failure ◽  
Ischemic Cardiomyopathy ◽  
Venous Blood ◽  
Relative Content ◽  
Red Bone Marrow ◽  
Healthy Donors ◽  
Monocyte Subpopulations ◽  
Classical Monocytes

The aim of the investigationwas to evaluate the ratio of classical (CD14++CD16-), intermediate (CD14++CD16+), nonclassical (CD14+CD16+) and transient (CD14+CD16–) monocytes in the blood and bone marrow in patients with chronic heart failure (CHF) against ischemic cardiomyopathy (ICMP).Materials and methods. 17 patients with ICMP and 14 practically healthy donors were observed. The material of the study was venous blood (in patients and healthy donors) and red bone marrow (in patients). In the materials the relative content of different monocytes subpopulations was determined by flow cytometry. The obtained results were analyzed by statistical methods.Results. It is shown that in the blood of patients the proportion of monocytes with the phenotype CD14++CD16- is 57.77 [of 46.35; 79.76]%, CD14++CD16+ – 25.06 [4.96; 42.31]%, CD14+CD16+ 5.05 [4.08; 6.58]% and CD14+CD16- – 6.03 [3.58; 10.89]%; in the bone marrow – 43.44 [40.54; 44.68]%, 0.16 [0; 1.07]%, 0,54 [0.35; 1.07]% and 54,32 [52.83; 56.08]%, respectively, which is different from the content of the data cells subpopulations in the blood (p < 0.05). At the same time, the content of non-classical monocytes in the patients’ blood is 2 times lower than in healthy donors, and the number of other cells varies within the norm.Conclusion. The differentiation of monocytes into 4 subpopulations in patients with CHF occurs directly in the bloodstream, since mainly the classical and transitional monocyte fractions with the prevalence of the latter are present in the bone marrow. Deficiency of non-classical monocytes of blood in CHF is probably associated with a disruption of their extramedullary differentiation.

238: Imaging of Transplanted Bone Marrow Derived Stem Cells for Therapy of Ischemic Cardiomyopathy

2010 ◽  
Vol 29 (2) ◽  
pp. S81-S82
Author(s):  
B. Bruckner ◽  
A. Ghodsizad ◽  
C. Piechaczek ◽  
A. Ruhparwar ◽  
M. Karck ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Ischemic Cardiomyopathy

Ruxolitinib Treatment Induces a Transition of Classical to Non-Classical Monocytes in Patients with Myelofibrosis

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2838-2838 ◽  
Author(s):  
Sanja Prijic ◽  
Taghi Manshouri ◽  
Ying Zhang ◽  
Ivo Veletic ◽  
Xiaorui Zhang ◽  
...  
Keyword(s):  
Bone Marrow ◽  
De Novo ◽  
Conflicts Of Interest ◽  
Myeloproliferative Neoplasm ◽  
Size Reduction ◽  
Spleen Size ◽  
Healthy Individuals ◽  
Normal Individuals ◽  
Monocyte Subpopulations ◽  
Classical Monocytes

Abstract Introduction: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm that develops de novo (primary myelofibrosis) or transforms from polycythemia vera or essential thrombocytosis. MF is characterized by stem cell-derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis, constitutional symptoms, cachexia, leukemic progression, and shortened survival. Several studies suggested that clonal monocytes play a role in the pathobiology of MF. However whether a specific monocyte subpopulation is predominantly present in MF is largely unknown. Traditionally, three subpopulations of CD14+ monocytes have been identified: classical (CD14++/CD16-), intermediate (CD14++/CD16+), and non-classical (CD14dim+/CD16++). Whether MF patients' monocyte subpopulations are different from those of normal individuals and how ruxolitinib treatment affects them has not been elucidated. Methods: Using flow cytometry we first assessed the distribution of the three monocyte subpopulations in the bone marrow (BM) of healthy individuals and MF and then assessed their distribution in BM samples from phase I/II clinical trial of ruxolitinib in patients with primary or secondary MF (Verstovsek S. etal. N Engl J Med 12:1117, 2010). Results: Using BM samples from 7 healthy individuals and 12 untreated MF patients we found a significant decrease in the percentage of monocytes (p =0.0061) in the mononuclear gate of untreated MF patients compared to normal individuals. However, the distribution of classical vs. non-classical monocyte subpopulations in MF was similar to that of normal BM (p =0.3, p =0.3, respectively). Remarkably, ruxolitinib treatment significantly altered the distribution of classical vs. non-classical monocyte subpopulations. During treatment (years 0-3, 3-6, 6-8) we identified a progressive increase in the percentage of monocytes in the mononuclear gate (p =0.1; p =0.04, and p =0.03, respectively) with a substantial increase in the non-classical monocyte subpopulation in years 0-3 and 3-6 of treatment (p= 0.04, p= 0.005, respectively) and a decrease in the classical monocytes (p =0.07, p =0.008, respectively). This trend reversed after 6-8 years of therapy (p =0.3, p =0.2, respectively). Importantly, in ruxolitinib-treated patients with a ≥50% spleen size reduction highest percentage of non-classical monocytes was observed during the first 3 years and years 3-6 of treatment (p =0.01, p =0.01, respectively). However during years 6-8 this difference was no longer detected and the percentage of non-classical monocytes was similar to the percentage detected in the pre-treatment BM samples (p =0.4). These changes correlated with response to ruxolitinib treatment. In patients with a <50% spleen size reduction the percentage of non-classical monocytes in years 0-3 of ruxolitinib treatment was significantly lower compared to patients with ≥50% spleen reduction (p =0.005), and patients with ≥50% spleen reduction show correlation between post-treatment spleen size and percentage of non-classical monocytes (p <0.0001, r=−0.4). Conclusions: Taken together, our results suggest that ruxolitinib induces a transition of classical to non-classical monocyte subpopulation during the first years of ruxolitinib treatment and that this effect correlates with the patients' clinical response. Further studies aimed at exploring the role of monocytes and their subpopulations in the pathobiology of MF are warranted. Disclosures No relevant conflicts of interest to declare.

Migration of Native Bone Marrow Cells to the Heart in Acute Non-Ischemic Cardiomyopathy

2010 ◽  
Vol 16 (8) ◽  
pp. S39
Author(s):  
Alejandro R. Trevino ◽  
Keith A. Youker ◽  
Luis J. Garcia ◽  
Wilbert L. Jones ◽  
Jerry Estep ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Ischemic Cardiomyopathy ◽  
Bone Marrow Cells ◽  
Native Bone ◽  
Marrow Cells

scholarly journals Functional recovery of patients with ischemic cardiomyopathy treated with coronary artery bypass surgery and concomitant intramyocardial bone marrow mononuclear cell implantation: A long term follow-up study

2015 ◽  
Vol 72 (3) ◽  
pp. 225-232 ◽  
Author(s):  
Zoran Trifunovic ◽  
Slobodan Obradovic ◽  
Bela Balint ◽  
Radoje Ilic ◽  
Zoran Vukic ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Ischemic Cardiomyopathy ◽  
Mononuclear Cells ◽  
Artery Bypass ◽  
Left Ventricular ◽  
Bone Marrow Mononuclear Cells ◽  
Cabg Surgery ◽  
To Receive

Background/Aim. Intramyocardial bone marrow mononuclear cells (BMMNC) implantation concomitant to coronary artery bypass grafting (CABG) surgery as an option for regenerative therapy in chronic ischemic heart failure was tested in a very few number of studies, with not consistent conclusions regarding improvement in left ventricular function, and with a follow-up period between 6 months and 1 year. This study was focused on testing of the hypothesis that intramyocardial BMMNC implantation, concomitant to CABG surgery in ischemic cardiomyopathy patients, leads to better postoperative long-term results regarding the primary endpoint of conditional status-functional capacity and the secondary endpoint of mortality than CABG surgery alone in a median follow-up period of 5 years. Methods. A total of 30 patients with ischemic cardiomyopathy and the median left ventricular ejection fraction (LVEF) of 35.9 ? 4.7% were prospectively and randomly enrolled in a single center interventional, open labeled clinical trial as two groups: group I of 15 patients designated as the study group to receive CABG surgery and intramyocardial implantation of BMMNC and group II of 15 patients as the control group to receive only the CABG procedure. All the patients in both groups received the average of 3.4 ? 0.7 implanted coronary grafts, and all of them received the left internal mammary artery (LIMA) to the left anterior descending (LAD) and autovenous to other coronaries. Results. The group with BMMNC and CABG had the average of 17.5 ? 3.8 injections of BMMNC suspension with the average number of injected bone marrow mononuclear cells of 70.7 ? 32.4 ? 106 in the total average volume of 5.7 ? 1.5 mL. In this volume the average count of CD34+ and CD133+ cells was 3.96 ? 2.77 ? 106 and 2.65 ? 1.71 ? 106, respectively. All the patients were followed up in 2.5 to 7.5 years (median, 5 years). At the end of the follow-up period, significantly more patients from the group that received BMMNC were in the functional class I compared to the CABG only group (14/15 vs 5/15; p = 0.002). After 6 months the results on 6-minute walk test (6-MWT) were significantly different between the groups (435 m in the BMMNC and CABG group and 315 m in the CABG only group; p = 0.001), and continued to be preserved and improved on the final follow-up (520 m in the BMMNC and CABG group vs 343 m in the CABG only group; p < 0.001). Cardiovascular mortality was also significantly reduced in the BMMNC and CABG group (p = 0.049). Conclusion. Implanatation of BMMNC concomitant to CABG is a safe and feasible procedure that demonstates not only the improved functional capacity but also a reduced cardiac mortality in a 5-year follow-up in patients with ischemic cardiomyopathy scheduled for CABG surgery.

scholarly journals C-CURE MULTICENTER TRIAL: LINEAGE SPECIFIED BONE MARROW DERIVED CARDIOPOIETIC MESENCHYMAL STEM CELLS FOR TREATMENT OF ISCHEMIC CARDIOMYOPATHY

2011 ◽  
Vol 57 (14) ◽  
pp. E200 ◽  
Author(s):  
Jozef Bartunek ◽  
William Wijns ◽  
Dariouch Dolatabadi ◽  
Marc Vanderheyden ◽  
Jo Dens ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Ischemic Cardiomyopathy ◽  
Multicenter Trial
Sign in / Sign up

Export Citation Format

Share Document